https://www.selleckchem.com/pr....oducts/Aminocaproic-
e contribution to pathology in cases of frontotemporal dementia and ALS. We aimed to report the long-term impact of modern chemotherapy and SABR dose regimens on oncologic outcomes of unresectable pancreatic adenocarcinoma (PA). We reviewed the treatment characteristics and outcomes of all patients who received multi-fraction SABR for unresectable PA between February 2007 and August 2018 at our institution. Time-to-events were calculated from date of diagnosis treating death as a competing risk. A total of 149 patients